Lurasidone for Pediatric Bipolar Disorder: A Systematic Review
Pharmaceuticals · 30.06.2025 · 18 (7) · 979
DOI: 10.3390/ph18070979 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 30.06.2025. Verfasst von Alexia Koukopoulos und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science, Health and Health Professions, Link Campus University, 00165 Rome, Italy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Lurasidone ((3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione) is a second-generation antipsychotic approved for schizophrenia and mood disorders. Adolescents and children with bipolar disorder receive treatments that expose them to weight gain and metabolic syndrome. Lurasidone is relatively free from such side effects, so it may constitute a useful alternative for the treatment of these patients. We focused on the use of lurasidone in children and adolescents with bipolar disorder.
Methods
On 11 June 2025, we used the following strategy on PubMed: lurasidone AND (“bipolar disorder” OR “bipolar depression” OR mania OR manic). We filtered for humans and ages 0–18 years and included case reports and clinical studies. Similar strategies adapted to each database were used to carry out our systematic review on CINAHL, PsycINFO/PsycARTICLES, Scopus, and the ClinicalTrials.gov register on the same date. We excluded reports without children/adolescent participants, those grouping adult participants with children/adolescents without providing data separately, reviews, and opinions/editorials with no data. Eligibility was determined through Delphi rounds; it was required that consensus was reached among all authors. We followed the PRISMA-2020 Statement.
Results
Our search produced 38 results on PubMed on 11 June 2025. We included four case reports/series and five studies. One additional eligible study emerged from our Scopus inquiry, raising the number of eligible studies to six. One case series was moderately positive; one case report was neutral, another was positive, and one reported the induction of mania. The six longitudinal studies involved 16,735 participants and showed generally good efficacy.
Conclusions
The use of lurasidone in adolescents/children with bipolar disorder obtains favorable results regarding the excitatory and depressive symptoms of bipolar disorder with no significant side effects.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Life Science, Health and Health Professions, Link Campus University, 00165 Rome, Italy.
- Department of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy.
- Department of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy.
- Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX 77030, USA.
ORCID-Profile: Claudia Calderoni, Georgios D Kotzalidis, Tommaso Callovini, Alessio Simonetti, Mario Pinto, Giovanni Camardese, Gabriele Sani
Zitieren
APA
Koukopoulos, A., Calderoni, C., Kotzalidis, G. D., Callovini, T., Moccia, L., Montanari, S., Autullo, G., Simonetti, A., Pinto, M., Camardese, G., Sani, G., & Janiri, D. (2025). Lurasidone for Pediatric Bipolar Disorder: A Systematic Review. Pharmaceuticals, 18(7), 979. https://doi.org/10.3390/ph18070979
Vancouver
Koukopoulos A, Calderoni C, Kotzalidis GD, Callovini T, Moccia L, Montanari S, et al. Lurasidone for Pediatric Bipolar Disorder: A Systematic Review. Pharmaceuticals. 2025;18(7):979. doi:10.3390/ph18070979
BibTeX
@article{Koukopoulos2025,
author = {Koukopoulos, Alexia and Calderoni, Claudia and Kotzalidis, Georgios D and Callovini, Tommaso and Moccia, Lorenzo and Montanari, Silvia and Autullo, Gianna and Simonetti, Alessio and Pinto, Mario and Camardese, Giovanni and Sani, Gabriele and Janiri, Delfina},
title = {Lurasidone for Pediatric Bipolar Disorder: A Systematic Review},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {7},
pages = {979},
doi = {10.3390/ph18070979}
}
EUVIMED